Page last updated: 2024-08-21

butyl isothiocyanate and Urinary Bladder Neoplasms

butyl isothiocyanate has been researched along with Urinary Bladder Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Blaheta, RA; Chun, FK; Cinatl, J; Grein, T; Haferkamp, A; Khadir, SE; Makhatelashvili, N; Mann, J; Maxeiner, S; Rutz, J; Sonnenburg, M; Thomas, A; Tsaur, I; Xie, H1

Other Studies

1 other study(ies) available for butyl isothiocyanate and Urinary Bladder Neoplasms

ArticleYear
Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
    International journal of molecular sciences, 2022, Sep-20, Volume: 23, Issue:19

    Topics: Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinases; Cyclins; Deoxycytidine; Gemcitabine; Humans; Isothiocyanates; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms

2022